37,00,000 a year, 10,000 per day: The scaring figures of doge bite in India
India's dog bite crisis is spiralling into a serious public health challenge, with numbers that experts describe as deeply alarming. In 2024 alone, the country recorded 37.17 lakh dog bite cases — averaging more than 10,000 incidents every single day. These figures reveal a widening gap between the Centre's goal of eliminating rabies by 2030 and the realities on the ground.
PTI A dog barks at children playing in the rain on the Kartavya Path, in New Delhi. India's dog bite crisis is escalating at a pace that public health experts find deeply alarming. In 2024 alone, the country recorded 37.17 lakh cases, an average of over 10,000 dog bites every single day. This surge points to a growing gap between disease prevention goals and on-ground realities.If one looks at official rabies death figures, the contrast is startling. Government data for 2022 recorded just 21 rabies deaths.
The WHO, using Indian government and other domestic sources, reported 305 deaths for the same year, as per The Times of India. Yet, WHO's modelling estimates 18,000–20,000 deaths annually in India -- more than 36% of global rabies fatalities. Most of these victims are children under 15, a group especially vulnerable to stray dog attacks. As per ToI analysis, dog bite cases dipped during the Covid years -- from 75.7 lakh in 2018 to just 17 lakh in 2021 -- but have surged again since, touching 37.2 lakh in 2024.
Maharashtra leads the tally with 13.5 lakh cases between 2022 and 2024, followed by Tamil Nadu (12.9 lakh) and Gujarat (8.4 lakh).As per the latest available census data from 2019, Uttar Pradesh had the highest stray dog population in India at 20.6 lakh, followed by Odisha with 17.3 lakh. Maharashtra and Rajasthan each reported 12.8 lakh strays, while Karnataka had 11.4 lakh.
A total of 26,334 dog bite cases have been reported in Delhi so far this year, official data accessed by PTI shown. Of these, 9,920 cases were recorded at Municipal Corporation of Delhi (MCD) hospitals, while 15,010 cases were reported at its anti-rabies vaccination (ARV) centres.MCD data indicates that 68,090 dog bite cases were recorded in the city in 2024. As of July 31 this year, Delhi has reported 49 cases of rabies, according to the data. Between January 25 and June 25, more than 65,000 stray dogs have been sterilised and vaccinated. During the same January–June period, the capital saw 35,198 animal bite incidents in total.The civic body has earlier announced plans to sterilise and vaccinate 97,994 dogs between April 2024 and December 2025. In comparison, 79,959 dogs were sterilised in 2023–24 and 59,076 in the preceding year.Karnataka has emerged as one of the most worrying hotspots, logging 3.6 lakh dog bites and 42 rabies deaths in 2024 alone. In just the past six months, the state recorded 2.3 lakh incidents and 19 deaths. Kerala too has seen a sharp spike in cases.According to ToI , Gurgaon has an estimated 50,000 stray dogs but only two operational shelters, each with a capacity of 50 animals, and two more under construction. The Animal Birth Control Rules, 2023, which require sterilised dogs to be returned to their original locations, have meant that large-scale shelter infrastructure was never developed. In Ghaziabad, the last census counted 48,000 stray dogs. Noida's situation is more severe -- with no official census, estimates put the stray population as high as 1.5 lakh, but the city has only four private shelters. In the past seven months alone, Noida has reported 73,754 street dog bite cases.Rabies is 100% preventable if victims receive prompt and complete post-exposure prophylaxis (PEP). Yet, India's combination of a vast stray population, patchy vaccination coverage, and poor public awareness continues to keep death rates high.The Centre has pledged to eliminate rabies by 2030, aligning with global health goals. But with millions of dog bites annually and a fatality burden vastly underreported, experts warn that bridging the gap between policy and practice will require sustained vaccination campaigns, strict stray control measures, and public education drives.
With inputs from ToI
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
44 minutes ago
- Time of India
Why US budget cuts could derail future mRNA vaccine progress
mRNA vaccines are credited with helping to end the COVID-19 pandemic and save millions of lives. Since then, researchers have been developing the technology to prevent a variety of infectious diseases and cancer. But experts warn this progress has been severely impacted after US health secretary Robert F Kennedy announced cuts to mRNA technology research. In total, the US health department will cancel contracts and withdraw $500 million (€427 million) of research funding, it announced on August 8. The announcement was the latest in a series of anti-science policies brought in by President Trump's second term in office, including a political take-over of federal research grants and withdrawing from the World Health Organization. What does this mean for the future of mRNA vaccine development? We take a look. mRNA vaccines have a long history of safety and efficacy mRNA vaccines were first tested in mice to vaccinate against flu in the 1990s, then first tested in humans in 2013 to vaccinate against rabies . It was thanks to these decades of research and testing that mRNA vaccine technology was ready and safe during the COVID-19 pandemic. Kennedy has been a longtime critic of the technology, saying in a video posted to social media platforms that mRNA programs are "troubled'. "We're prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don't collapse when viruses mutate," Kennedy said in the video. What other types of vaccine are in development? There are many types of vaccines in development that have different methods of helping the body to fight a virus. Each technology has advantages and limitations which depend on the disease, the target population, and practical considerations like production speed and costs. Vaccine technology platforms include live (but weakened) and deactivated "whole" pathogen vaccines. The polio vaccine is available in both forms, for example. There are also toxoid-based vaccines, which use inactivated bacterial toxins. Then there are viral vector vaccines, which train the immune system by introducing tiny viral pathogenic fragments into the body. DNA-based therapies are also being considered as another way to provide an accurate target for a human immune response. Luka Cicin-Sain, a viral immunologist at Germany's Helmholtz Centre for Infection Research, is leading the development of a respiratory syncytial virus (RSV) vaccine. The RSV vaccine is a viral vector product, which uses a low-risk mouse virus to deliver the RSV spike protein to the human immune system. Though still being tested, Cicin-Sain is hopeful that his platform will provide long-lasting immunity against RSV with a single immunization dose. Are other types of vaccines as good as mRNA vaccines? Despite the promise these other vaccine technologies have shown, they haven't had the same impact as their mRNA cousin. That's because the benefit of using mRNA technology as vaccines is the ability to quickly adapt their use for new pathogens. "Once you know the structure of the virus, the genetics of the virus, then you can produce a vaccine extremely rapidly," said Penny Ward, a pharmaceutical physician at Kings College London, UK. In some cases, mRNA vaccines can be more effective at training the body's immune response to a pathogen. "We don't seem to produce the same immune response to a DNA vaccine as we have to a [m]RNA vaccine," said Ward. Will a loss for mRNA research be a gain for other vaccines? There is no guarantee the $500 million funding will flow to other vaccine research. Kennedy is a longtime vaccine critic — he has fired the panel that makes vaccine recommendations and shared anti-vax sentiment, including during a measles outbreak in the US in May. Cicin-Sain worries that defunding one branch of vaccine science hinders overall progress in the research field. "I'm not saying that mRNA vaccines can solve everything, but why deny yourself a tool in your toolkit?" Cicin-Sain said. Kennedy's funding cuts will slow down RNA technology development, Cicin-Sain said, and drive American scientists to compete for funding outside the US, diminishing ongoing vaccine science. Will others step in to fund mRNA vaccine research ? While other private and philanthropical research funds do exist to fund mRNA vaccine technologies, it's unlikely they can fill the $500 million gap left by the Trump administration's cuts. There's also no guarantee other national governments will step in to fill the US void. "The funding in Europe has been stagnant," said Cicin-Sain. "And there are not so many [private] investors out there who think that vaccines are the best way to put their VC [venture capital] at work," he added. Ward highlighted another problem with cuts to publicly funded vaccine research — governments who fund vaccine research get first access to successful products, which is why Brits were among the first to get the Oxford-AstraZeneca vaccine. "Government funding secures access for countries that are part funders for those products," Ward told DW. If private funders step in to fund mRNA vaccine research, it could reduce people's access to those vaccines at an affordable price. "If progress is to be made, and there's no source of government funding, the industry will fund [research] if they believe there's a market, but that will be reflected in the price of the eventual product,' Ward said. "No matter how you slice or dice, the net effects are going to be negative," Cicin-Sain said.
Time of India
2 hours ago
- Time of India
Investors see growth in single-specialty hospitals
Representative image NEW DELHI: With traditional multi-specialty hospital chains nearing deal saturation, investors are increasingly shifting their focus on single-specialty hospitals (SSHs), which are fast emerging as the next growth frontier in India's healthcare landscape. Offering focused care, operational efficiency and faster scalability, SSHs have become particularly attractive to private equity (PE) firms, analysts told TOI. This shift is reflected in deal activity: SSHs now account for over half of all hospital transactions by volume, supported by $2.3 billion in PE investments over the past three years, according to data from Grant Thornton Bharat. Over the past decade, deal volumes in India's single-specialty hospital segment remained steady, peaking in 2023. The year 2023 saw the highest deal value of $1.2 billion, largely driven by landmark transactions such as BPEA EQT's investment in Indira IVF and Quadria's strategic investments in Maxivision and NephroPlus. Next growth frontier Sunil Thakur, partner at Quadria Capital, says, "Projected to more than double to $9 billion by 2028, organised single-specialty networks offer compelling economics, (>20% earnings before interest, taxes, depreciation, and amortisation, 20-25% return on capital employed) powered by deep specialisation and rapid access expansion. The momentum is evident from the fact that over $3.5 billion of PE capital has flowed into the segment in recent years. " The segment is growing at a robust 24% annually - outpacing the 15-17% growth seen in multi-specialty counterparts -indicating strong investor confidence. Key specialties driving this growth include, in vitro fertilisation (IVF), women's and child care, eye care, nephrology, and oncology - each witnessing substantial deal activity. "Investor interest in the segment has remained consistent, though we are yet to see a large-value deal in 2025. Strong fundamentals, including healthy margins, better unit economics, scalability, asset-light models, and quicker break-even cycles, continue to attract both strategic and financial investors. As healthcare delivery expands beyond metro cities, single-specialty formats are increasingly seen as effective platforms for regional growth," says Bhanu Prakash Kalmath SJ, Partner and Healthcare Leader, Grant Thornton Bharat. Valued at approximately $15 billion, the SSH market includes an organised segment worth around $4 billion, which continues to gain scale through consolidation and network expansion. The focus on single-specialty hospitals is a global phenomenon, reflecting a broader shift towards specialised, efficient healthcare delivery, experts say. Vishal Bali, executive chairman Asia Healthcare Holdings, a platform focused on single-specialty hospitals, backed by TPG and Singapore-based GIC, says: "We strongly believe that one of the key prescriptions to bridge India's demand-supply gap in healthcare delivery sits with SSH enterprises." Stay informed with the latest business news, updates on bank holidays , public holidays , current gold rate and silver price .
The Print
2 hours ago
- The Print
Rajasthan CM Sharma felicitates MBBS intern for academic excellence
Komal Verma Saluja, who secured 67th rank in NEET-UG 2020, and scored the highest marks in the 2023 MBBS examination conducted by the Rajasthan University of Health Sciences, is currently pursuing her internship, officials said. Several social workers and folk artistes from across the state were also felicitated for their contributions to their respective fields at the event held on the eve of Independence Day on Thursday. Kota (Rajasthan), Aug 15 (PTI) Rajasthan Chief Minister Bhajanlal Sharma has felicitated a Kota-based MBBS intern with a certificate of appreciation for her academic feats during the 'At Home' event at the Maharangarh Fort in Jodhpur, officials said. She was selected for the prestigious Khorana Programme of Scholars, a research internship programme for students in biotechnology and allied fields, besides publishing research papers in a number of journals on several topics, including radiology and rheumatology. Speaking after being felicitated by the chief minister, Komal emphasised the importance of discipline and genuine passion for achieving goals. 'I know success in medicine is not a sprint but a marathon. I am thankful to my family members, principal and teachers, who guided, motivated and pushed me forward,' she said. 'My goal is to serve humanity through evidence-based medicine,' Komal added. PTI COR APL ARI This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
